3.0.0 2543 2022-11-01T13:49:51Z 2022-11-01T14:33:43Z Senate S 2019-09-25 116 ssfi00 Finance Committee Senate Standing Reported original measure 2019-09-25T16:58:27Z S. Rept. 116-120 Star Rating for Biosimilars Act 116 4629 HR 2019-10-18 Sponsor introductory remarks on measure. (CR H8232) Related bill CRS Drug Price Transparency in Medicaid Act of 2019 116 5281 HR 2019-12-04 Referred to the Subcommittee on Health. Related bill CRS Payment Commission Data Act of 2019 116 1264 HR 2019-02-15 Referred to the Subcommittee on Health. Related bill CRS Payment Commission Data Act of 2019 116 1781 HR 2019-10-29 Received in the Senate and Read twice and referred to the Committee on Finance. Related bill CRS Improving Low-Income Access to Prescription Drugs Act of 2019 116 3029 HR 2019-06-04 Subcommittee Hearings Held. Related bill CRS Capping Drug Costs for Seniors Act of 2019 116 4649 HR 2019-10-30 Sponsor introductory remarks on measure. (CR H8607) Related bill CRS A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information. 116 801 S 2019-03-14 Read twice and referred to the Committee on Finance. Related bill CRS Improving Low Income Access to Prescription Drugs Act of 2019 116 1999 S 2019-06-27 Read twice and referred to the Committee on Finance. Related bill CRS GENE Therapy Payment Act 116 5882 HR 2020-02-12 Referred to the House Committee on Energy and Commerce. Related bill CRS Prescription Drug Pricing Reduction Act of 2020 116 4199 S 2020-07-02 Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228) Related bill CRS Medicare Prescription Drug Fraud Prevention Act of 2019 116 1505 S 2019-05-16 Read twice and referred to the Committee on Finance. Related bill CRS 2019-09-25 Senate Placed on Senate Legislative Calendar under General Orders. Calendar No. 225. Calendars 2019-09-25 ssfi00 Finance Committee Senate Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120. Committee 2019-09-25 Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120. Committee 14000 9 Library of Congress ssfi00 Finance Committee 2019-09-25 Introduced in Senate IntroReferral 10000 9 Library of Congress G000386 Sen. Grassley, Chuck [R-IA] Charles Grassley R IA E. N 2019-09-26T15:47:40Z Status of CBO’s cost estimate for S. 2543, the Prescription Drug Pricing Reduction Act of 2019 https://www.cbo.gov/publication/55663 Letter to the Honorable Chuck Grassley Health Accounting and auditing Administrative law and regulatory procedures Appropriations Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Fraud offenses and financial crimes Genetics Government information and archives Government studies and investigations Health care costs and insurance Health care coverage and access Health care quality Health technology, devices, supplies Home and outpatient care Hospital care Indian social and development programs Inflation and prices Intergovernmental relations Manufacturing Medicaid Medical ethics Medicare Minority health Prescription drugs Public contracts and procurement Public participation and lobbying Retail and wholesale trades Social work, volunteer service, charitable organizations State and local government operations Health 00 2019-09-25 Introduced in Senate 2020-02-20T20:36:48Z Prescription Drug Pricing Reduction Act of 2019

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

  • requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
  • requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
  • reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
  • requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
  • requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
  • increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.
]]> 25 2019-09-25 Reported to Senate 2020-02-24T18:43:04Z Prescription Drug Pricing Reduction Act of 2019

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

  • requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
  • requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
  • reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
  • requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
  • requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
  • increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.
]]> Prescription Drug Pricing Reduction Act of 2019 Display Title Prescription Drug Pricing Reduction Act of 2019 Short Title(s) as Reported to Senate Prescription Drug Pricing Reduction Act of 2019 S Senate Reported to Senate RS Official Title as Introduced An original bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes. Reported to Senate 2019-09-25T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116s2543rs/xml/BILLS-116s2543rs.xml 2019-09-25 Placed on Senate Legislative Calendar under General Orders. Calendar No. 225. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.